HeyJaredPT Jyothi Datta
- Indexed articles, last 90 days
- 34
- Latest publication
- Sep 27, 2026
- Outlet visibility, for The Hindu BusinessLine
- Top 50K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
PB Healthâs hospital expansion plans on track: PB Fintech Chairman and Group CEO (opens the original)
Read excerpt
PB Health is a separate venture and will see no change in its hospital expansion plans, said Yashish Dahiya, Chairman and Group Chief Executive Officer of PB Fintech Limited - the parent company of Policybazaar. Responding to whether a possible impact on its insurance business from a recently proposed policy change would cast a shadow on its healthcare investment plans, Dahiya told businessline, PB Health is a totally separate venture with its own team and execution. âSo no, that doesnât get
After two overseas buys, Poly Medicure doubles down on domestic manufacturing (opens the original)
Read excerpt
With two overseas acquisitions in the bag, medical devices maker Poly Medicure is focussing on shoring up its domestic manufacturing in segments including cardiac and orthopaedic products. “So every year, the plan is [for] the next four years, by FY30, we plan to launch 25, 30 new products every year,” said Himanshu Baid, Managing Director, Poly Medicure Ltd, adding that the focus would be on cardiac, orthopaedic, nephrology, gastro, and oncology products. “We have around 390 patents …and we are
Ozempic & Wegovy maker Novo looks to expand India portfolio through investments in new technologies (opens the original)
Read excerpt
Danish healthcare company Novo Nordisk is open to invest in technologies that innovate, even personalise treatment for diabetes and obesity, said a top company executive. Novo’s globally popular Ozempic and Wegovy, used in treating diabetes and obesity, respectively – are both available in India. “We are looking across the gamut of delivery in innovation, be it gene-based therapy or mRNA technology, for example,” said Jay Thyagarajan, Novo Nordisk Senior Vice President (APAC). “So we are actuall
Maharashtra FDAâs hospital consumables prices survey: Hospitals call for evidence-based framework (opens the original)
Read excerpt
The Maharashtra Food and Drug Administrationâs recent survey flagging huge mark-ups on hospital consumables may have resonated with people who have had to contend with high treatment costs and non-transparent bills. But an industry body representing healthcare companies including hospitals â Nathealth has called for a ânuancedâ discussion to come out with a framework for transparent pricing, taking into account all that goes into delivering a product for better clinical outcomes. Â Â The
Encourage a âreverse brain drainâ to move from generics to innovation: Clincial research industry (opens the original)
Read excerpt
Encourage a reverse âbrain drain,â say representatives of the clinical research community citing the China example as a suggestion to help the Indian biopharmaceutical industry make the research journey from generics to innovative medicines. Over a 15 years-plus timeframe, China has created an innovative ecosystem and are today able to have âan inside-out product ...from China to the world,â Anirban Roychowdhury, Honorary General Secretary with the Indian Society for Clinical Research (I
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For The Hindu BusinessLine, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.